TY - JOUR
T1 - Effects of statin therapy on the progression of chronic kidney disease
AU - Shah, Samir
AU - Paparello, James
AU - Danesh, Farhad R.
N1 - Funding Information:
Supported by grants from the NIH (RO1-DK 67604), and the American Diabetes Association (F.R.D.).
PY - 2005/4
Y1 - 2005/4
N2 - Statins are lipid-lowering agents that specifically, competitively, and reversibly inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in the formation of cholesterol. A large body of evidence from numerous, well-controlled, randomized trials demonstrates that statins significantly reduce fatal and nonfatal cardiovascular events in the general population. Cardiovascular benefits of statins have been conventionally attributed to reduction in levels of low-density lipoprotein cholesterol. More recently, subanalyses of large clinical trials suggest that statins may also prove beneficial in ameliorating the progression of kidney disease through their cholesterol-dependent and/or cholesterol-independent (pleiotropic) effects. This review focuses on the role of statin therapy in the progression of chronic kidney disease, the published trials that study the effect of antilipidemic agents on nephropathy, and the emerging pleiotropic effects of statins on the kidneys.
AB - Statins are lipid-lowering agents that specifically, competitively, and reversibly inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in the formation of cholesterol. A large body of evidence from numerous, well-controlled, randomized trials demonstrates that statins significantly reduce fatal and nonfatal cardiovascular events in the general population. Cardiovascular benefits of statins have been conventionally attributed to reduction in levels of low-density lipoprotein cholesterol. More recently, subanalyses of large clinical trials suggest that statins may also prove beneficial in ameliorating the progression of kidney disease through their cholesterol-dependent and/or cholesterol-independent (pleiotropic) effects. This review focuses on the role of statin therapy in the progression of chronic kidney disease, the published trials that study the effect of antilipidemic agents on nephropathy, and the emerging pleiotropic effects of statins on the kidneys.
KW - Cardiovascular disease
KW - Cholesterol
KW - Chronic renal disease
KW - Dyslipidemia
KW - Statin
UR - http://www.scopus.com/inward/record.url?scp=16844368589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16844368589&partnerID=8YFLogxK
U2 - 10.1053/j.ackd.2005.01.007
DO - 10.1053/j.ackd.2005.01.007
M3 - Article
C2 - 15822054
AN - SCOPUS:16844368589
SN - 1548-5595
VL - 12
SP - 187
EP - 195
JO - Advances in Chronic Kidney Disease
JF - Advances in Chronic Kidney Disease
IS - 2
ER -